{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-029396","form_type":"8-K","ticker":"ENGN","cik":"0001980845","company_name":"enGene Therapeutics Inc.","filed_at":"2024-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.409388+00:00","generated_at":"2026-06-05T00:08:51.515653+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"enGene Q1 net loss $10.7M; CEO to resign; $200M PIPE extends cash into 2027","bullets":["Net loss $10.7M ($0.46/share) vs $8.6M ($13.29/share) YoY; operating expenses $10.8M vs $4.6M.","Completed $200M oversubscribed PIPE (20M shares at $10, 31% premium); net proceeds $187.5M.","Cash $85.6M as of Jan 31; with PIPE proceeds, expects runway into 2027.","CEO Jason Hanson to resign upon appointment of successor; Board conducting search.","Pivotal Phase 2 LEGEND study for EG-70 in NMIBC on track; interim data mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-029396","json":"https://secwatch.observer/filing/0000950170-24-029396.json","markdown":"https://secwatch.observer/filing/0000950170-24-029396.md","text":"https://secwatch.observer/filing/0000950170-24-029396.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1980845/000095017024029396/0000950170-24-029396-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1980845/000095017024029396/engn-20240311.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T00:08:51.515653+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"308840d9d0f59ec6ad74d5a83679ebfb8b2f49d3","claim":"enGene Therapeutics Inc. reported first quarter ended January 31, 2024 results: net income net loss attributable to common shareholders was $10.7 million, or $0.46 per share.","evidence_excerpt":"enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced its financial results for the first quarter ended January 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1980845/000095017024029396/0000950170-24-029396-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended January 31, 2024"},{"label":"Net income","value":"net loss attributable to common shareholders was $10.7 million, or $0.46 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}